

Second U.S. commercial customer - Northeast Georgia Health System

Salix® platform including Plaque module integrated into clinical workflow

PERTH, Australia, 08 December 2025: Artrya Limited (ASX: AYA) (**Artrya** or the **Company**), a medical technology company commercialising its Salix® AI-powered cloud platform, for the near real time, point of care assessment and management of coronary artery disease, is pleased to announce it has secured its second U.S. customer with the signing of a commercial agreement for the use of its Salix® platform with Northeast Georgia Health System.

Key Points

- U.S. foundation partner, Northeast Georgia Health System (NGHS), becomes Artrya's second U.S. commercial customer
- Three-year commercial agreement with a minimum value of US\$0.3M for the Salix® Coronary Anatomy platform, with additional fee-per-scan revenue from the Salix® Coronary Plaque module and, following FDA clearance, the Salix® Coronary Flow module.
- Salix® platform to be rolled out across NGHS' network of hospitals and used by NGHS' employed cardiology group, Georgia Heart Institute
- Artrya's Customer Success team in Atlanta to support rollout, onboarding and training, clinician engagement and provides technical support

John Konstantopoulos, Co-Founder and CEO of Artrya, commented:

"We are proud to secure our second U.S. commercial customer through this three-year commercial agreement with Northeast Georgia Health System, a respected leader in patient care across the U.S. Southeast. This builds our long-standing partnership to validate Salix® in their workflow, and we are excited to roll out Salix® across the Northeast Georgia Health System network. We remain on track to convert all three U.S. foundation partners to commercial customers this year, where our new Customer Success team is already playing a leading role in integration and support."

Mudassar Ahmed, MD, MBA, Chief Cardiology Officer for Georgia Heart Institute, commented:

"The Salix® platform will now go live in our clinical workflow, which represents an important step forward in how we deliver cardiovascular care. At Georgia Heart Institute, we are committed to adopting technologies that not only enhance diagnostic precision but also transform the patient journey. Through our work during the past two years, we have seen that Salix® can bring a new dimension to our practice by supporting earlier identification of risk and enabling more proactive treatment strategies."

Zaid Said, MD, FACC, Medical Director of Cardiac CT and MRI for Georgia Heart Institute, commented:

"Integrating Salix® into our workflow will help streamline interpretation, reduce variability, and deliver actionable insights for our patients at the point of care. This latest A.I.-enabled technology reflects our commitment to advancing cardiovascular medicine and ensures patients across Georgia Heart Institute can benefit from faster, more accurate diagnoses and improved outcomes."

Commercial Agreement for clinical use of the Salix® platform

Artrya has signed a three-year commercial agreement with Northeast Georgia Health System (**NGHS**), one of its three U.S. foundation partners, marking another significant milestone in the Company's accelerating U.S. expansion strategy. Under the contract, Salix® Coronary Anatomy will be licensed as a SaaS platform with a fixed monthly subscription fee over a 36-month term, while assessments performed using the Salix® Coronary Plaque module will generate fee-per-scan revenue.

This agreement follows a period of close collaboration between Artrya and NGHS to validate and integrate Salix® Coronary Anatomy platform. Recent efforts have focused on testing the Salix® platform into NGHS's clinical workflow, enabling seamless interaction with both the Picture Archiving and Communication System (**PACS**) and the Electronic Medical

Record (EMR) systems. Salix® will now be used in routine care for patients with suspected or confirmed coronary artery disease undergoing CT angiography, across NGHS's five hospitals, outpatient centres, and physician practices within the Georgia Heart Institute. NGHS is a leading not-for-profit health network with more than 1.6 million patient visits annually, comprising five hospitals and an extensive network of outpatient facilities. At its core is the Georgia Heart Institute, one of the largest cardiology programs in the state, serving more than 100,000 patients each year.

Artrya is also preparing the FDA submission for the Salix® Coronary Flow module, which will expand the Company's product offering and will be activated for clinical use upon FDA clearance. Both the Plaque and Flow modules are eligible for reimbursement under Category I CPT codes, further strengthening the commercial opportunity.

To support its growing U.S. customer base and anticipated expansion, Artrya has established a Customer Success team in Atlanta. This team will serve as a technology and support hub, providing technical integration expertise, clinician engagement, and comprehensive customer support on the ground.

Material terms of the agreement

The full details of the Commercial Agreement are commercial in confidence, with the material points as follows:

- Commercial SaaS Licence Agreement for non-exclusive use of the Salix® Coronary Anatomy platform for clinical use
- Monthly subscription fee over the duration for use of the Salix® Coronary Anatomy platform
- Fee per scan revenue to be charged for use of Salix® Coronary Plaque
- Salix® Coronary Flow will be available for clinical use by Northeast Georgia Health System, post FDA clearance
- Once the Salix® Coronary Flow module receives FDA clearance, each CCTA scan analysed will attract a fee per scan, which will also be eligible for U.S. reimbursement under a Category 1 CPT code
- Three-year term for the agreement with standard provisions for events of default
- Termination with 30 days' notice with no cancellation fees
- Customary terms include security and privacy protocols, support levels, software upgrades.

- Ends -

This ASX Announcement is authorised for release by the Board of Artrya Limited.

About Artrya

Artrya Limited (ASX:AYA) is an Australian medical technology company developing AI-powered solutions to improve the detection and management of coronary artery disease. Its proprietary software analyses coronary CT scans to identify key biomarkers of heart disease, supporting clinicians in diagnosing patients more accurately and efficiently. Artrya's mission is to advance cardiac care through innovative technology, with regulatory and commercial activities underway across key international markets.

For more information visit www.artrya.com or follow us on LinkedIn at www.linkedin.com/company/artrya

Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (**Estimates** and **Projections**). Forward-looking statements can generally be identified by the use of forward-looking words such as "expect", "anticipate", "likely", "intend", "should", "could", "may", "predict", "plan", "propose", "will", "believe", "forecast", "estimate", "target", "outlook", "guidance" and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of Artrya. The Estimates and Projections are based on information available to Artrya as at the date of the Announcement, are based upon management's current expectations, estimates, projections, assumptions and beliefs in regards to future events in respect to Artrya's business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an

indication or guarantee of future performance. The bases for these statements are subject to risk and uncertainties that might be out of control of Artrya and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by Artrya in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. Artrya takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.

For more information:

Corporate Enquiries

John Konstantopoulos

Co-Founder and Chief Executive Officer

Tel: +61 8 6478 7816

Email: contact@artrya.com

Investor & Media Enquiries

David Allen or John Granger

Hawkesbury Partners

Tel: +61 499 100 038 or +61 410 577 155

Email: investors@artrya.com